# Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/furmonertinib-ast2818-versus-gefitinib-as-first-line-therapy-for-chinese/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Yuankai Shi,Gongyan Chen,Xiang Wang,Yunpeng Liu,Lin Wu,Yanrong Hao,Chunling Liu,Shuyang Zhu,Xiaodong Zhang,Yuping Li,Jiwei Liu,Lejie Cao,Ying Cheng,Hui Zhao,Shucai Zhang,Aimin Zang,Jiuwei Cui,Jian Feng,Nong Yang,Fei Liu,Yong Jiang,Chuan Gu |
| Citations | 233 |
| DOI | 10.1016/s2213-2600(22)00168-0 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4281984185 |
| PMID | 35662408 |
| Type | article |
| Year | 2022 |

## Paper authors

- [Ying Cheng](https://scholariq.org/researchers/ying-cheng/)
- [Lin Wu](https://scholariq.org/researchers/lin-wu/)
- [Nong Yang](https://scholariq.org/researchers/nong-yang-2/)

## Paper journal

- [The Lancet Respiratory Medicine](https://scholariq.org/journals/the-lancet-respiratory-medicine/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.